These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 8594426

  • 1. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH.
    N Engl J Med; 1996 Mar 14; 334(11):682-7. PubMed ID: 8594426
    [Abstract] [Full Text] [Related]

  • 2. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M.
    N Engl J Med; 1996 Mar 14; 334(11):677-81. PubMed ID: 8594425
    [Abstract] [Full Text] [Related]

  • 3. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.
    N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR.
    N Engl J Med; 1992 Apr 09; 326(15):975-82. PubMed ID: 1545850
    [Abstract] [Full Text] [Related]

  • 5. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G.
    N Engl J Med; 1998 Feb 12; 338(7):409-15. PubMed ID: 9459643
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P, Carnovali M, Marchiori A, Galilei Investigators.
    Arch Intern Med; 2004 May 24; 164(10):1077-83. PubMed ID: 15159264
    [Abstract] [Full Text] [Related]

  • 7. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1695-702. PubMed ID: 14585937
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J, Riess H, Büller HR, Brom J, Weidinger G, Huisman MV.
    Haematologica; 2003 Oct 30; 88(10):1157-62. PubMed ID: 14555312
    [Abstract] [Full Text] [Related]

  • 10. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
    Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S.
    Am J Hematol; 2001 May 30; 67(1):10-4. PubMed ID: 11279651
    [Abstract] [Full Text] [Related]

  • 11. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    N Engl J Med; 2003 Jul 10; 349(2):146-53. PubMed ID: 12853587
    [Abstract] [Full Text] [Related]

  • 12. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L.
    Thromb Haemost; 1998 May 10; 79(5):897-901. PubMed ID: 9609216
    [Abstract] [Full Text] [Related]

  • 13. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Barsotti A, Corsi M, Vasdekis S, Christopoulos D, Lennox A, Malouf M.
    Angiology; 1999 Oct 10; 50(10):781-7. PubMed ID: 10535716
    [Abstract] [Full Text] [Related]

  • 14. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D.
    N Engl J Med; 1993 Nov 04; 329(19):1370-6. PubMed ID: 8413432
    [Abstract] [Full Text] [Related]

  • 15. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
    Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B.
    N Engl J Med; 1997 Sep 04; 337(10):663-9. PubMed ID: 9278462
    [Abstract] [Full Text] [Related]

  • 16. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
    Labas P, Ohrádka B, Vladimír J, Cambal M.
    Int Angiol; 2000 Dec 04; 19(4):303-7. PubMed ID: 11305727
    [Abstract] [Full Text] [Related]

  • 17. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S.
    Arch Intern Med; 1993 Jul 12; 153(13):1541-6. PubMed ID: 8391792
    [Abstract] [Full Text] [Related]

  • 18. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM.
    Semin Thromb Hemost; 2001 Oct 12; 27(5):513-8. PubMed ID: 11668421
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
    Kearon C.
    Curr Opin Pulm Med; 2007 Sep 12; 13(5):398-402. PubMed ID: 17940484
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
    Ugaki H, Enomoto T, Fujiwara K, Kimura T, Kawasaki T.
    Blood Coagul Fibrinolysis; 2008 Sep 12; 19(6):585-9. PubMed ID: 18685443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.